logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Nov 2021
Inhibrx, Inc.
Additional data from phase I trial of INBRX-109
Conventional chondrosarcoma
Q4 2021
ERYTECH Pharma S.A
Initial data from phase II clinical trial of Eryaspase in combination with gemcitabine and carboplatin compared to chemotherapy(TRYbeCA-2)
Triple-negative breast cancer
Q4 2021
Windtree Therapeutics Inc.
Data from phase 2 global study of Istaroxime
Early cardiogenic shock
Q4 2021
Kronos Bio Inc
Initial safety, pharmacokinetic and pharmacodynamic data from phase 1/2 clinical trial of KB-0742
MYC-amplified solid tumors
Q4 2021
Cardiff Oncology, Inc.
Data readout from phase II trial of Onvansertib in combination with abiraterone and prednisone
Abiraterone-resistant metastatic castrate-resistant prostate cancer
Q4 2021
NextCure Inc
Data from Phase 2 monotherapy trial of NC318
Non-small cell lung cancer (NSCLC) adenocarcinoma cohort
Q4 2021
Molecular Templates Inc.
Additional data from dose escalation portion and metastatic breast cancer dose expansion cohort from Phase 1 study of MT-5111
HER2-positive cancers

Q4 2021
NLS Pharmaceutics AG
Topline data from phase II trial of Quilience
Narcolepsy
Oct 2021
Adaptimmune Therapeutics plc
Update on phase I trial radiation sub-study of ADP-A2M4
Multiple tumor
Q4 2021
Galmed Pharmaceuticals Ltd.
Histology results from one-third of the study population of open label part of phase III study of Aramchol (ARMOR)
Nonalcoholic steatohepatitis, or NASH, and fibrosis
Early Q4 2021
Entasis Therapeutics Holdings Inc
Topline data from phase III registration trial of SUL-DUR ( ATTACK)
Patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii
Q4 2021
Cerevel Therapeutics Holdings Inc.
Data from Phase 1 proof-of-principle trial of Darigabat
Acute anxiety in healthy volunteers
Q4 2021
Checkpoint Therapeutics, Inc.
Full top-line results from Registration-Enabling Trial of Cosibelimab
Metastatic Cutaneous Squamous Cell Carcinoma
Early Q4 2021
Histogen Inc.
26 -week Study results from phase Ib/IIa clinical trial of HST-001
Androgenic alopecia in men
Q4 2021
Adial Pharmaceuticals, Inc
Data readout from Phase 3 pivotal trial of AD04 (ONWARD)
Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms in adults
Q4 2021
Aeglea BioTherapeutics, Inc.
Topline data from pivotal Phase III trial of Pegzilarginase (PEACE)
Arginase 1 Deficiency
Late Q4 2021
Aileron Therapeutics, Inc.
Initial results from Phase 1b clinical trial of ALRN-6924
Advanced non-small cell lung cancer (NSCLC) receiving first-line carboplatin doublet chemotherapy
Q4 2021
Brickell Biotech, Inc.
Topline results from phase III program of Sofpironium bromide gel, 15% (Cardigan II Study)
Primary axillary (underarm) hyperhidrosis patients in aged nine and older
Q4 2021
Brickell Biotech, Inc.
Topline results from phase III program of Sofpironium bromide gel, 15% (Cardigan I Study)
Primary axillary (underarm) hyperhidrosis patients in aged nine and older
Q4 2021
RELMADA THERAPEUTICS, INC.
Results from phase II trial of REL-1017 as a monotherapy
Major depressive disorder
Q4 2021
ObsEva SA
Readout from phase III trial of Yselty (EDELWEISS 3)
Endometriosis
Q4 2021
Applied Genetic Technologies Corp.
Preliminary 3-month data from phase I/II clinical trials evaluating AAV gene therapy product candidates (ACHMA3 )
Pediatric patients with achromatopsia caused by CNGA3 mutations
Q4 2021
Applied Genetic Technologies Corp.
Preliminary 3-month data from phase I/II clinical trials evaluating AAV gene therapy product candidates (ACHMB3 )
Pediatric patients with achromatopsia caused by CNGB3 mutations
Q4 2021
Bellus Health Inc
BLU.TO, BLU, BLU
Topline data from phase 2b clinical trial of BLU-5937 (SOOTHE)
Refractory chronic cough
Q4 2021
CNS Pharmaceuticals Inc
Interim data from phase II study of Berubicin
Glioblastoma